Medi-Mibi

Technetium (99mTc) Sestamibi, the active ingredient in Medi-Mibi, is a radiopharmaceutical presented as an injection for intravenous use. It is employed to assess myocardial perfusion during cardiac stress testing and related diagnostic procedures.

GNH USA supplies Medi-Mibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Medi-Mibi is used in cardiac imaging to evaluate blood flow and perfusion of the heart muscle.

- Myocardial perfusion imaging: enables visualization of regional blood flow to detect perfusion defects. - Cardiac stress testing: helps identify coronary artery disease by comparing rest and stress images. - Ischemic heart disease assessment: provides functional information on the extent and severity of myocardial ischemia.

Adverse reactions may occur following administration of Medi-Mibi.

Common Side Effects: - Warmth or flushing at the injection site - Mild nausea or metallic taste - Transient headache - Injection site pain or bruising - Light‑headedness - Temporary feeling of warmth throughout the body

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Significant hypotension - Cardiac arrhythmia - Radiation‑induced skin injury at the injection site - Pulmonary embolism (very rare)

Medi-Mibi should be used with attention to patient safety and handling requirements.

- Pregnancy: avoid unless essential, as fetal effects are unknown. - Breastfeeding: consider discontinuation of nursing or assess risk‑benefit. - Known hypersensitivity: do not administer to patients with documented allergy to technetium‑based agents. - Renal impairment: assess renal function and adjust protocol if necessary. - Ensure adequate patient hydration before and after injection to facilitate tracer clearance. - Store at ambient temperature: keep in original container, protect from light and moisture.

Interactions with other agents may affect image quality or patient safety.

Major Interactions (Avoid): - Iodinated contrast media: can interfere with tracer distribution and imaging interpretation. - High‑dose thallium agents: may compete for myocardial uptake.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt heart rate response during stress testing. - Calcium channel blockers: can alter myocardial perfusion patterns. - Vasodilators (e.g., dipyridamole, adenosine): require protocol adjustment to avoid overlapping effects.